| Literature DB >> 20664697 |
Naresh Polisetti1, Prasoon Agarwal, Imran Khan, Paturu Kondaiah, Virender S Sangwan, Geeta K Vemuganti.
Abstract
PURPOSE: Limbal stem cell deficiency is a challenging clinical problem and the current treatment involves replenishing the depleted limbal stem cell (LSC) pool by either limbal tissue transplantation or use of cultivated limbal epithelial cells (LEC). Our experience of cultivating the LEC on denuded human amniotic membrane using a feeder cell free method, led to identification of mesenchymal cells of limbus (MC-L), which showed phenotypic resemblance to bone marrow derived mesenchymal stem cells (MSC-BM). To understand the transcriptional profile of these cells, microarray experiments were carried out.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20664697 PMCID: PMC2903463
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Sequence of the primer used for RT–PCR amplification of selected genes to substantiate the results obtained by microarray.
| 1 | Vascular Endothelial Growth factor A (VEGF-A) | ATGCGGATCAAACCTCACC | ATCTGGTTCCCGAAACCCTG | |
| | 183 | | | 358 |
| | 165 | | | 304 |
| | 148 | | | 269 |
| | 121 | | | 172 |
| 2 | Fibroblast Growth Factor 2 (FGF2) | GGAGAAGAGCGACCCTCAC | GTGCCACATACCAACTGGTG | 221 |
| 3 | (Angiopoietin 1 (Ang-1) | CCCAGAAACTTCAACATCTGG | GGACTGTGTCCATCAGCTC | 537 |
| 4 | Transforming growth factor, beta 1 (TGFB1) | GACTACTACGCCAAGGAGGTC | TCAACCACTGCCGCACAACTC | 332 |
| 5 | Nestin (NES) | CACCTGTGCCAGCCTTTCTTAA | CCACCGGATTCTCCATCCTTA | 361 |
| 6 | Neuron-specific class III beta-tubulin (Tuj1) | TCAAGCGCATCTCCGAGCAG | ACCGTAAAACGTCAGGCCTGGAG | 444 |
| 7 | Collagen 1 alpha 1 | TCCCCAGCCACAAAGAGTCTA | TTTCCACACGTCTCGGTCA | 201 |
| 8 | Vimentin` | CAGGAACAGCATGTCCAAATCG | TGTACCATTCTTCTGCCTCCTGC | 127 |
| 9 | S100A2 | GATCCATGATGTGCAGTTCTCT | GTTCTGCTTCAGGGTCGGT | 310 |
| 10 | RPL35A | GAACCAAAGGGAGCACACAG | CAATGGCCTTAGCAGGAAGA | 236 |
| 11 | PAX-6 | GAATCAGAGAAGACAGGCCA | GGTAGGTATCATAACTCCG | 302 |
| 12 | S100A4 | GATGAGCAACTTGGACAGCAA | CTGGGCTGCTTATCTGGGAAG | 123 |
| 13 | E-cadherin | AAGGTGACAGAGCCTCTGGATAGA | TCTGATCGGTTACCGTGATCAA | 124 |
| 14 | CD24 | AACTAATGCCACCACCAAGG | CCTGTTTTTCCTTGCCACAT6 | 188 |
| 15 | PBX-1 | ACCCTTCGCCATGTTATCAG | ATTGCTGGGAGATCAGTTGG | 189 |
| 16 | OTX-1 | CTCCACCCAGCTGTTAGCAT | CGCATGAAGATGTCAGGGTA | 221 |
| 17 | FOXA1 | AGGGCTGGATGGTTGTATTG | AGGCCTGAGTTCATGTTGCT | 150 |
| 18 | SHC3 | GACATCTACAGCACGCCAGA | CAAGGGCTGGTTCTTGAGAG | 186 |
| 19 | FOXF1 | TTGGCAATATTTGCCGTGTA | CTGCACTCTAGCAGCCAAAA | 209 |
| 20 | CDH6 | TCGAGAAAACAGGGAGCAGT | CGGTGGAGAAGATTCAGGAG | 175 |
| 21 | CDH11 | GTGCCTGAGAGGTCCAATGT | GGGTAGGGCTGTTCTGATGA | 165 |
| 22 | Collagen VI alpha 1 | ACAGTGACGAGGTGGAGATCA | GATAGCGCAGTCGGTGTAGG | 122 |
| 23 | Collagen IV alpha 2 | TTGGCGGGTGTGAAGAAGTTT | CCTTGTCTCCTTTACGTCCCTG | 178 |
| 24 | IL-1B | GGGCCTCAAGGAAAAGAATC | TTCTGCTTGAGAGGTGCTGA | 205 |
| 25 | Fibronectin 1 | GCAGTAACCACTATTCCTGCAC | TCCTGATACAACCACGGATGAG | 192 |
| 26 | T-cell differentiation protein 2 (MAL2) | TTGCCTCCTCCAATGTTCCTC | CAGTTAGCATCAATTTGAGCCAC | 133 |
| 27 | CTGF | CAGCATGGACGTTCGTCT | CCAACCACGGTTTGGTCCTT | 117 |
| 28 | SPARC (osteonectin) | CGAGACCTGTGACCTGGACAATG | TCCGGTACTGTGGAAGGAGTGG | 127 |
| 29 | Sflt-F | TGAGCACTGCAACAAAAAGG | TCCTCCGAGCCTGAAAGTTA | 172 |
| 30 | FLT-F | GGCTCTGTGGAAAGTTCAGC | GCTCACACACTGCTCATCCAAA | 223 |
| 31 | FGFR1, transcript variant 2 mRNA | TCCAGTGCATCCATGAACTCT | CTGTTGCGTCCGACTTCAA | 268 |
| 32 | Brain derived nerve growth factor | GATGCTCAGTAGTCAAGTGCC | GCCGTTACCCACTCACTAATAC | 168 |
| 33 | Chemokine (C-C motif) ligand 2 | CAGCCAGATGCAATCAATGCC | TGGAATCCTGAACCCACTTCT | 190 |
| 34 | Chitanase 3 like 1 | GAAGAGGCCCTGTCTAGGTA | AGATGATGTGGGTACAGAGG | 250 |
| 35 | Matrix Metallo proteinase 2 (MMP2) | CCGTCGCCCATCATCAAGTT | CTGTCTGGGGCAGTCCAAAG | 169 |
| 36 | Interleukin 1 aplha (IL-1A) | TGTGACTGCCCAAGATGAAG | CGCCTGGTTTTCCAGTATCT | 238 |
| 37 | Decorin | AGTTGGAACGACTTTATCTGTCC | GTGCCCAGTTCTATGACAATCA | 160 |
| 38 | Neurotrophin tyrosine kinase receptor 2 | GATAAGCTGGACTCGGCACG | GGACGACATCCCTAGCAGCC | 152 |
| 39 | Connexin 43 | TGTCCTTAAGTCCCTGCTAA | GTAGCTGAGGAATGATGAAAAAG | 245 |
Figure 1Morphological features of mesenchymal cells of limbus. Limbal explant cultures having epithelial (E) and mesenchymal cells (S; 200×; A). Cell sphere formation in the MC-L cultures giving impression of embryoid body formation (200×; B). Spindle shaped morphology of MC-L forming colonies (200×; C). Culture of MC-L showing both spindle shaped and broad flattened cells (arrows; 200×; D)
Figure 2Characterization of limbal explant culture derived epithelial (LEC) and mesenchymal like cells (MC-L). Following immunoctytochemical analysis (A-L) epithelial cells showing positive for ABCG2 (A), CK3/CK12 (B; green fluorescence), CK19 (C; red fluorescence), CK14 (D), E-Cadherin (E), vimentin (F; green fluroscence), double immunostaining for PAX-6 (green fluorescence) and vimentin (red fluorescence; G). Mesenchymal like cells of limbus (H-L) showing positive for vimentin (H) and negative for cytokeratin 3/12 (I), cytokeratin 14(J), CD34 (K), and nestin (L). Nuclear staining was performed with propidium iodide (red; A, B, D, E, H-L). Scale bar=20 µm (A-C, E-H, and J) and 10µm (D, I, K, L). Flow cytometry analysis (M-V) was performed by incubation of the mesenchymal like cells of limbus with the indicated antibodies. M: Isotype controls for FITC and PE, N: CD90 FITC and CD44 PE, O: CD40-FITC and HLA-ABC PE, P: CD11b FITC and HLA-ABC PE, Q: CD34 FITC and CD10 PE R: Isotype control for FITC and APC, S: CXCR4 APC and CD90 FITC, T: CD40L APC and CD40 FITC, U: Isotype control for FITC and PerCP, V: CD138 PerCP and CD13 FITC.
The differential gene expression between LEC, MC-L and MSC-BM, as measured by the fold change difference of the corresponding genes (Ribosomal genes excluded). Abbreviations: LEC – limbal epithelial cells, MC-L – mesenchymal like cells of limbus, MSC-BM – mesenchymal stem cells of bone marrow.
| Keratin 12, T-cell differentiation protein 2 (MAL2), Nebulette, v-myc myelocytomatosis viral related oncogene, ets homologous factor, calbindin 1, Kringle containing transmembrane protein 2, glucosaaminyl (N-acetyl) transferase 2, carcinoembryonic antigen-related cell adhesion molecule 6, Apolipoprotein B mRNA editing enzyme catalytic polypeptide –like 3a, tumor associated calcium signal transducer 1, sciellin, serine peptidase inhibitor kazal type 5, carcinoembryonic antigen-related cell adhesion molecule 1, interleukin 1 alpha, interleukin 18, dual adaptor of phosphotyrosine and 3-phosphoinositides (DAPP1), Transmembrane channel-like 5, claudin 1, defensin beta 1, WAP four-disulfide core domain 5, chemokine (C-X-C motif) ligand 1, dystonin, desmocollin 2, cadherin 1, transforming growth factor alpha, S100 calcium binding protein A8, Serpin peptidase inhibitor clade B member 5, visinin-like 1, interleukin 1 beta, desmoglein 3, matrix metallopeptidase 10, tumor protein p73-like (p63), homeoboxdomain-only protein (HOP), amphiregulin. |
| Vascular endothelial growth factor receptor 1, cadherin 6, forkhead box F1, glutamate receptor ionotrophic, collectin sub-family member 12, SHC (Src homology 2 domain containing) transforming protein 3 (SHC3), AF052115, BC073929. |
| growth differentiation factor 6 (GDF6), Urea transporter, erythrocyte (SLC14A1), neurotrophic tyrosine kinase, receptor, type 2 (NTRK2), early growth response 2 (Kro × −20 homolog, Drosophila) (EGR2), secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) (SPP1), myogenic factor 6 (herculin) (MYF6), collagen, type XI, alpha 1 (COL11A1), olfactomedin 4 (OLFM4), hepatitis A virus cellular receptor 2 (HAVCR2), homeo box A11, antisense (HOXA11S) on chromosome 7, homeobox C9 (HOXC9), HELAD1S mRNA for helicase, phosphodiesterase 1C, calmodulin-dependent 70 kDa, opioid binding protein/cell adhesion molecule-like (OPCML), transcript variant 2, zinc finger, matrin type 4 (ZMAT4), |
| semaphorin 3D (SEMA3D), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), vitrin (VIT), Lysophosphatidic acid receptor Edg-7 (LPA receptor 3) (LPA-3), keratin 18 (KRT18), transcript variant 1, insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), myelin basic protein (MBP), contactin 3 (plasmacytoma associated) (CNTN3), |
| nucleosome assembly protein 1-like 3 (NAP1L3), thymocyte selection-associated high mobility group box (TOX), axin 2 (conductin, axil) (AXIN2), phosphodiesterase 11A (PDE11A), potassium voltage-gated channel, Isk-related family, member 4 (KCNE4), dermatan sulfate epimerase-like (DSEL), chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1), G protein-coupled receptor 124 (GPR124), protocadherin 18 (PCDH18), hyaluronan and proteoglycan link protein 1 (HAPLN1), collagen, type V, alpha 2 (COL5A2), alpha-2-macroglobulin (A2M), decorin (DCN), cerebellar degeneration-related protein 1, 34 kDa (CDR1), ependymin related protein 1 (zebrafish) (EPDR1), formin 2 (FMN2), Platelete derived growth factor receptor alpha, frizzled homolog 7, dapper, antagonist of beta-catenin, homolog 3, microfibrillar associated protein 5, lysyl oxidase, integrin, alpha 8, junctional adhesion molecule 2, protein kinase C, alpha, platelet-derived growth factor receptor, beta polypeptide. |
Differential gene expression between LEC and MC-L in growth factors and cytokine related genes.
| amphiregulin (schwannoma-derived growth factor) (AREG) | 167.6 (Down) | 131.25 (down) | 3.74 (down) |
| transforming growth factor, alpha (TGFA) | 57.21 (down) | 28.49 (down) | |
| fibroblast growth factor binding protein 1 (FGFBP1) | 38.75 (down) | 23.011 (down) | |
| fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) (FLT1) | 31.0 (up) | | 96.42 (down) |
| Platelet derived growth factor receptor alpha (PDGFRA) | 26.10 (up) | 33.93 (up) | |
| platelet-derived growth factor receptor, beta polypeptide (PDGFRB) | 20.52 (up) | 21.90 (up) | |
| insulin-like growth factor binding protein 5 (IGFBP5) | 17.65 (up) | 14.81 (up) | |
| growth factor receptor-bound protein 14 (GRB14) | 17.23 (down) | 5.82 (down) | 2.95 (down) |
| fibroblast growth factor 2 (basic) (FGF2) | 13.78 (up) | | |
| fibroblast growth factor 11 (FGF11) | 12.83 (down) | | |
| keratinocyte growth factor-like protein 1 (KGFLP1) | 10.9 (up) | | 9.85 (up) |
| fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) (FGFR1) | 10.50 (up) | 8.96 (up) | |
| insulin-like growth factor 2 (somatomedin A) (IGF2) | 9.9 (up) | 6.2 (up) | |
| connective tissue growth factor (CTGF) | 9.77 (up) | 15.45 (up) | 2.3 (up) |
| pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) (PTN) | 8.54 (up) | 9.9 (up) | |
| insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) | 8.10 (up) | | |
| fibroblast growth factor 1 (acidic) (FGF1) | 8.03 (up) | 5.41 (up) | 7.41 (down) |
| Insulin-like growth factor binding protein 4 (IGFBP4) | 7.65 (up) | 14.2 (up) | 2.96 (up) |
| fibroblast growth factor 7 (keratinocyte growth factor) (FGF7) | 7.51 (up) | 15 (up) | 4.51 (up) |
| platelet derived growth factor D (PDGFD) | 5.97 (up) | 12.7 (up) | |
| fibroblast growth factor binding protein 3 (FGFBP3) | 5.68 (up) | 4.4 (up) | |
| insulin-like growth factor binding protein 5 (IGFBP5) | 5.61 (up) | 5.4 (up) | 2.95 (down) |
| fibroblast growth factor receptor 2 (fgfr2) | 4.50 (down) | | 4.89 (up) |
| Hepatocyte growth factor precursor (Scatter factor) (SF) (Hepatopoeitin-A) | 4.05 (up) | 10.06 (up) | |
| transforming growth factor beta 1 induced transcript 1 (TGFB1I1), transcript variant 2 | 3.94 (up) | 2.97 (up) | |
| nerve growth factor, beta polypeptide (NGFB) | 3.83 (up) | | 2.6 (down) |
| chemokine (C-X-C motif) ligand 2 (CXCL2) | 79.06 (down) | 4.5 (down) | |
| chemokine (C-X-C motif) ligand 3 (CXCL3) | 26.25 (down) | 16.0 (down) | 3.88 (up) |
| chemokine (C-X-C motif) ligand 1 (CXCL1) | 65.87 (down) | 64.9 (down) | |
| chemokine (C-X-C motif) ligand 11 (CXCL11) | 58.344 (down) | 14.42 (down) | |
| chemokine (C-X-C motif) ligand 10 (CXCL10) | 7.71 (down) | 6.97 (down) | |
| chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (CXCL12) | 34.26 (up) | 82.68 (up) | |
| chemokine (C-C motif) ligand 26 (CCL26) | 11.4 (up) | 2.49 (up) | |
| chemokine (C-C motif) ligand 2 (CCL2) | 23.43 (up) | | 3.48 (down) |
| chemokine (C-C motif) ligand 13 (CCL13) | 12.42 (up) | | 2.34 (up) |
| interleukin 1, alpha (IL1A) | 78.72 (down) | 63.61 (down) | |
| interleukin 1, beta (IL1B) | 48.57 (down) | 28.89 (down) | |
| interleukin 1 receptor, type II (IL1R2) | 12.17 (down) | 21.03 (down) | 3.92 (up) |
| interleukin 1 receptor antagonist (IL1RN) | 20.06 (down) | 15.10 (down) | |
| interleukin 20 receptor, alpha (IL20RA) | 210.69 (down) | | |
| interleukin 18 (interferon-gamma-inducing factor) (IL18) | 78.26 (down) | 56.72 (down) | |
| interleukin 23, alpha subunit p19 (IL23A) | 28.40 (down) | 29.29 (down) | |
| interleukin 11 receptor, alpha (IL11RA) | 15.58 (up) | | |
| neurotrophin 5 (NTF5) | 14.96 (down) | 11.64 (up) | |
| neurotrophin 3 (NTF3) | 16.40 (up) | 7.50 (up) | 7.48 (down) |
| nerve growth factor, beta polypeptide (NGFB) | 3.8 (up) | | |
| Glial cell line-derived neurotrophic factor precursor (Astrocyte- derived trophic factor 1) | 4.24 (up) | 6.56 (up) | |
| GDNF family receptor alpha 1 (GFRA1) | 6.5 (up) | 6.28 (up) | |
| brain-derived neurotrophic factor (BDNF) | 9.15 (up) | 3.69 (up) | 8.68 (down) |
Comparisons of genes expressed in MC-L and in MSC-BM cells for selected terms of gene ontology. Abbreviations: LEC – limbal epithelial cells, MC-L – Mesenchymal like cells of limbus, MSC-BM – Mesenchymal stem cells of bone marrow. All the genes are highly expressed (up) except those in brackets (down).
| Osteonectin | 5.8 | 3.89 | |
| Collagen, type I, alpha 2 | 10.7 | 10.15 | |
| Connective tissue growth factor | 9.7 | 15.45 | |
| Collagen, type V alpha 2 | 16.7 | 22.2 | |
| Osteopontin | | 3.8 | 29.4 |
| Runt related transcription factor 2 | | 5.9 | 5.5 |
| PDZ and LIM domain 7, transcript variant 4 | 5.3 | 3.29 | |
| Gremlin 2 | 16.1 | 14.29 | |
| Transgelin | 4.2 | 5.31 | |
| Meltrin alpha | 10 | 13.78 | |
| Myosin light chain 9, transcript variant 2 | 4.7 | 4.87 | |
| Synocoilin 1 | 8.2 | 5.7 | |
| Tropomyosin1 (alpha), transcript variant 3 | 4.7 | 6.84 | |
| Tropomyosin 2 (beta), transcript variant 2 | 3.5 | 3.75 | |
| Caldesmon 1, transcript variant 1 | 13.8 | 17.7 | |
| Desmuslin, transcript variant A | 26.4 | 27.9 | |
| Leiomodin 1 | 8.5 | 9.29 | |
| Leptin Receptor | 4.94 | 60.58 | 26.74 |
| Leptin | | 6.24 | 6.89 |
| Serum amyloid A1, Transcript variant 1 | 6.8 (down) | 4.2 (down) | 7.7 |
| CCAAT/enhancer binding protein alpha | 4.8 (down) | | 3.23 |
| Fibromodulin | 10.1 | 13.82 | |
| Decorin, transcript variant A1 | 27.6 | 41.45 | |
| Cartilage oligomeric matrix protein | | 8.4 | 11.15 |
| Tensin 1 | 14.9 | 10.31 | |
| Hyaluronan and proteoglycan link protein | 31 | 47.45 | |
| Collaten, type XI, alpha 1 | | 60.18 | 46.12 |
| Chitanase 3-like 1 | | 4.72 | 5.68 |
| Microfibrillar associated protein 5 | 24 | 28.12 | |
| Syndecan 2 | 12.1 | 16.7 | |
| Matrix-remodelling associated 5 | 11.3 | 7.2 | |
| Chondroitin sulfate proteoglycan 4 | 8.3 | 7.5 | |
| Collagen, type VIII, alpha 1, transcript variant 1 | 8.6 | 5.39 | |
| Procollagen-lysine 1,2-oxoglutarate 5-dioxygenease 1 | 3.2 | 3.3 | |
| Low density lipoprotein-related protein 12 | 3.43 | 3.3 | |
| Notch homolog 2 | 3.78 | 5.2 | |
| Collagen, type VI alpha 1 | 3.9 | 2.39 | |
| Cysteine-rich, angiogenic inducer, 61 | 4 | 4.8 | |
| Glial cell line-derived neurotrophic factor precursor | 4.2 | 6.5 | |
| Endoglin | 4.29 | 4.17 | |
| Collagen, type 1, alpha 2 | 4.3 | 3.3 | |
| Leukemia inhibitory factor receptor alpha (LIFR) | 4.46 | 5.9 | |
| Neuropilin 1 | 4.6 | 4.1 | |
| Colony stimulating factor 1 (Macrophage) | 5.6 | 15.09 | |
| Wingless-type MMTV integration site family, member 5B | 5.7 | 6.06 | |
| Neuronal growth regulator 1 | 6.13 | 8.06 | |
| Noggin | 6.2 | 3.7 | |
| Matrix metallopeptidase 2 | 6.27 | 6.2 | |
| Collagen, type VI, alpha 3, transcript variant 4 | 6.27 | 8.4 | |
| Neuronal PAS domain protein 1 | 6.38 | 5.7 | |
| Fibroblast growth factor receptor 1 | 6.45 | 8.9 | |
| Neuropilin 1, transcript variant 1 | 6.7 | 8.3 | |
| Collagen, type VI, alpha 2 | 7.4 | 6.2 | |
| Collagen, type VI, alpha 1 | 8.0 | 10.2 | |
| Bone marrow stromal cell antigen | 8.2 | 8.4 | |
| Collagen, type V, alpha 1 | 8.4 | 9.3 | |
| Fibronectin 1, transcript variant 7 | 9.24 | 10.14 | |
| Fibroblast growth factor receptor 1, transcript variant 1 | 10.5 | 7.6 | |
| Collagen, type 1 alpha 2 | 10.7 | 10.15 | |
| Angiopoietin 1 | 14.8 | 17.1 | |
| Neuronal cadherin | 8.4 | 13.5 | |
Figure 3Validation of microarray data by Real time RT–PCR. The individual gene-specific values thus calculated were averaged to mean±standard deviation and fold change was expressed as log 2 ratios (y-axis).
Figure 4Validation of micro array data by semiquantitative RT–PCR. Reverse transcription polymerase chain reaction analysis of the selected differentially expressed genes. Ribosomal protein large 35 (RPL35) was served as an internal control. Abbreviations: LEC – limbal epithelial cells, MC-L – mesenchymal cells of limbus, MSC-BM – mesenchymal stem cells of bone marrow, -RT – no reverse trasncriptase, CDH1 – cadherin 1 (E-cadherin), COLVIA1 – collagen 6 alpha 1, COL4A2 – collagen 4 alpha 2, IL-1B – interleukin 1 beta, FN1 – fibronectin 1, MAL2 - T-cell differentiated antigen 2, CTGF – Connective tissue growth factor, FGFR1 – fibroblast growth factor receptor 1, BDNF – brain derived nerve growth factor, CCL2 – chemokine ligand 2, CHI3L1 – chitanase 3 like 1, MMP2 – matrix metallo peptidase 2, IL1A – interleukin 1 alpha, KRT7- cytokeratin 7, DCN – decorin, Ang 1 – angiopoientin, bFGF – basic fibroblast growth factor, NTRK2 – neurotrophin tyrosine kinase receptor 2.